Macimorelin
Aliases: Macrilen · AEZS-130
Last verified: 2026-09-23
The short version
An oral GH secretagogue — FDA-approved as a diagnostic test for adult GH deficiency (the only oral GHS diagnostic).
Identity & type
- Molecular type
- mali molekul
- Origin
- An oral GH secretagogue — FDA-approved as a diagnostic test for adult GH deficiency (the only oral GHS diagnostic).
Mechanism of action
GHS-R1a agonism → acute GH spike (diagnostic).
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 0.5 mg/kg orally once (test).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
0.5 mg/kg orally once (test). A diagnostic drug — no community experiences; a transient GH spike.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A diagnostic drug — no community experiences; a transient GH spike.
Protocol — official vs community
Official / label
Macrilen: 0.5 mg/kg orally once, as a single dose of granules — the only approved use is the diagnosis of adult growth hormone deficiency.
Duration: Single administration; serum GH is measured at timed intervals after dosing under supervision.
A diagnostic tool, not a therapy — the transient GH pulse exists to read the pituitary's response, nothing more. No approved repeat-dosing or chronic regimen exists.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
FDA-approved 2017.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Dysgeusia, dizziness, mild nausea.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials